SGMO Financial Facts
Collaboration agreements: 2.73MResearch and development: 17.01M
See Full Income Statement
Accounts receivable: 1.48M
Total stockholders' equity: 143.84M
See Full Balance Sheet
Sangamo Biosciences Inc. (SGMO) Earnings
|
Expand Research on SGMO
| Next EPS Date | 5/1/24 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -48.2% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/8/18 |  |
Q118 | -$0.23 | $0.48 | -$0.71 | $12.64M | $53.09M | = |  | | Details |
| 8/8/23 | Q223 | -$0.66 | -$0.35 | -$0.31 | $6.84M | $13.26M | N/A | | | Details | |
| 11/1/23 | Q323 | -$0.59 | -$0.32 | -$0.27 | $9.39M | $9.36M | N/A | | | Details | |
| 5/8/19 | |
Q119 | -$0.41 | -$0.25 | -$0.16 | $8M | $22.82M | N/A | | | Details |
8/3/16  |
|
Q216 | -$0.38 | -$0.24 | -$0.14 | $3.7M | $5.38M | = | | | Details |
| 11/8/18 | |
Q318 | -$0.13 | $0.00 | -$0.13 | $23.6M | $26.96M | N/A | | | Details |
| 3/13/24 | Q423 | -$0.34 | -$0.26 | -$0.08 | $2.04M | $8.11M | N/A | | | Details | |
| 2/24/21 | |
Q420 | -$0.29 | -$0.21 | -$0.08 | $25.8M | $32.15M | N/A | | | Details |
